{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:00:53Z","timestamp":1775664053970,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2008,8,9]],"date-time":"2008-08-09T00:00:00Z","timestamp":1218240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s10072-008-0947-9","type":"journal-article","created":{"date-parts":[[2008,8,8]],"date-time":"2008-08-08T10:08:09Z","timestamp":1218190089000},"page":"233-234","source":"Crossref","is-referenced-by-count":17,"title":["Cyclophosphamide-based combination therapies for autoimmunity"],"prefix":"10.1007","volume":"29","author":[{"given":"Paola","family":"Perini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,9]]},"reference":[{"key":"947_CR1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0049-0172(83)90016-1","volume":"12","author":"J. Kovarsky","year":"1983","unstructured":"Kovarsky J (1983) Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases. Semin Arthritis Rheum 12:359\u2013372","journal-title":"Semin Arthritis Rheum"},{"key":"947_CR2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.7326\/0003-4819-122-12-199506150-00009","volume":"122","author":"D.T. Boumpas","year":"1995","unstructured":"Boumpas DT, Austin HA 3rd, Fessler BJ et al (1995) Systemic lupus erythematosus: emerging concepts. Part 1: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 122:940\u2013950","journal-title":"Ann Intern Med"},{"key":"947_CR3","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1212\/WNL.58.12.1856","volume":"58","author":"T.H. Brannagan 3rd","year":"2002","unstructured":"Brannagan TH 3rd, Pradhan A, Heiman-Patterson T et al (2002) Highdose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 58:1856\u20131858","journal-title":"Neurology"},{"key":"947_CR4","first-page":"52","volume":"12","author":"S.A. Gauthier","year":"2005","unstructured":"Gauthier SA, Weiner HL (2005) Cyclophosphamide therapy for MS. Int MS J 12:52\u201358","journal-title":"Int MS J"},{"key":"947_CR5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/14740338.6.2.183","volume":"6","author":"P. Perini","year":"2007","unstructured":"Perini P, Calabrese M, Rinaldi L, Gallo P (2007) The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf 6:183\u2013190","journal-title":"Expert Opin Drug Saf"},{"key":"947_CR6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1172\/JCI3125","volume":"102","author":"M. Comabella","year":"1998","unstructured":"Comabella M, Balashov K, Issazadeh et al (1998) Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 102:671\u2013678","journal-title":"J Clin Invest"},{"key":"947_CR7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ana.410420307","volume":"42","author":"D.R. Smith","year":"1997","unstructured":"Smith DR, Balashov KE, Hafler DA et al (1997) Immune deviation following pulse cyclophosphamide\/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol 42:313\u2013318","journal-title":"Ann Neurol"},{"key":"947_CR8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1073\/pnas.94.2.599","volume":"94","author":"K.E. Balashov","year":"1997","unstructured":"Balashov KE, Smith DR, Khoury SJ et al (1997) Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A 94:599\u2013603","journal-title":"Proc Natl Acad Sci U S A"},{"key":"947_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2004.04.013","volume":"223","author":"H.L. Weiner","year":"2004","unstructured":"Weiner HL (2004) Immunosuppressive treatment in multiple sclerosis. J Neurol Sci 223:1\u201311","journal-title":"J Neurol Sci"},{"key":"947_CR10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1191\/1352458505ms1210oa","volume":"11","author":"D.R. Smith","year":"2005","unstructured":"Smith DR, Weinstock-Guttman B, Cohen JA et al (2005) A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 11:573\u2013582","journal-title":"Mult Scler"},{"key":"947_CR11","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1007\/s00415-004-0581-2","volume":"251","author":"F. Patti","year":"2004","unstructured":"Patti F, Reggio E, Palermo F et al (2004) Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. J Neurol 251:1502\u20131506","journal-title":"J Neurol"},{"key":"947_CR12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/jnnp.71.3.404","volume":"71","author":"F. Patti","year":"2001","unstructured":"Patti F, Cataldi ML, Nicoletti F et al (2001) Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 71:404\u2013407","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-008-0947-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-008-0947-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-008-0947-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:11:36Z","timestamp":1559121096000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-008-0947-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,9]]},"references-count":12,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["947"],"URL":"https:\/\/doi.org\/10.1007\/s10072-008-0947-9","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,9]]}}}